|
DGFT extends MIP on key chemical intermediate of Cholesterol lowering drug ATS-8 imports till Nov-30
|
|
Shardul Nautiyal, Mumbai
October 03 , 2026
|
|
|
The Directorate General of Foreign Trade (DGFT) has extended the Minimum Import Price (MIP) on key chemical intermediate of cholesterol lowering medication ATS-8 imports till November 30, 2026. This condition is imposed on specific items covered under Chapter 29 of ITC (HS), 2022, Schedule-I of the Import Policy. The move continues the existing import policy condition and maintains the prescribed price threshold for imports of the specified chemical.
ATS-8, chemically known as (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate (CAS No. 125971-94-0), is a key chiral chemical intermediate used primarily in the synthesis of atorvastatin calcium, a widely prescribed statin drug for lowering cholesterol.
The extension has been notified by the Department of Commerce (DoC) through DGFT Notification No. 026/2026-27 dated September 2026. The notification states that the MIP condition was originally imposed through Notification No. 30/2025-26 dated September 18, 2025.
Under the extended provision, a MIP of US$ 111 per kg on Cost, Insurance and Freight (CIF) value will continue to apply to imports of ATS-8, identified as {(4R-Cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate}.
The condition applies to ATS-8 imported under the specified ITC (HS) codes, namely 29329990, 29339990, 29333990, 29321990, 29349990, 29420090, 29189990, 29159099, 29163990 and 29225090.
For pharmaceutical manufacturers, chemical suppliers and exporters involved in APIs, intermediates and other pharmaceutical inputs, the continuation of the MIP condition is relevant to import planning, sourcing costs and landed-cost calculations. Importers dealing in the specified product will need to continue factoring the prescribed CIF-based threshold into their commercial and supply-chain arrangements through November 30, 2026.
The DGFT has clarified that the extension is being made with all other terms and conditions of the earlier notification remaining unchanged. Therefore, the latest notification does not introduce a fresh set of conditions for the specified item but extends the validity of the existing MIP requirement for the stated period.
The notification has been issued in exercise of the powers conferred under Sections 3 and 5 of the Foreign Trade (Development & Regulation) Act, 1992, read with paragraphs 1.02 and 2.01 of the Foreign Trade Policy 2023, as amended from time to time.
The DGFT notification states that the decision has been issued with the approval of the minister of commerce & industry.
The stated objective of continuing the MIP condition is to maintain the prescribed import-price requirement for the identified chemical while retaining the other provisions of the existing notification. The extension also provides clarity to importers and downstream industries, including pharmaceutical and chemical manufacturers, on the applicable import policy until the revised end date.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|